Upstream Bio, Inc. ( (UPB) ) has released its Q1 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its investors.
Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, with its lead product candidate, verekitug, being the only monoclonal antibody in clinical development targeting the TSLP receptor.
In its first quarter of 2025 financial results, Upstream Bio reported significant progress in its clinical programs, particularly with its lead candidate, verekitug, which is being developed for multiple severe respiratory diseases. The company has accelerated its guidance on several clinical milestones, including the expected release of top-line data from its Phase 2 trial for chronic rhinosinusitis with nasal polyps in the third quarter of 2025.
Key financial highlights include a net loss of $27.3 million for the first quarter of 2025, an increase from the $10.9 million loss in the same period of 2024, primarily due to higher research and development expenses related to the verekitug program. The company also reported having $431.4 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2027. Additionally, Upstream Bio plans to initiate a Phase 2 clinical trial for chronic obstructive pulmonary disease in mid-2025.
The company is also preparing to release top-line data from its Phase 2 trial for severe asthma in the first half of 2026 and is initiating a long-term safety and efficacy extension study for severe asthma. These developments underscore Upstream Bio’s commitment to advancing verekitug through clinical trials with the potential for regulatory approval.
Looking ahead, Upstream Bio remains focused on achieving its clinical milestones and advancing its pipeline. The management is optimistic about the potential of verekitug to address unmet needs in severe respiratory diseases, and the company is well-positioned financially to continue its development activities through 2027.